287 related articles for article (PubMed ID: 1664130)
1. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
Aurelian L; Smith CC; Wachsman M; Paoletti E
Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
[TBL] [Abstract][Full Text] [Related]
2. Regulation of expression of herpes simplex virus (HSV) glycoprotein D in vaccinia recombinants affects their ability to protect from cutaneous HSV-2 disease.
Wachsman M; Aurelian L; Smith CC; Perkus ME; Paoletti E
J Infect Dis; 1989 Apr; 159(4):625-34. PubMed ID: 2538519
[TBL] [Abstract][Full Text] [Related]
3. Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D.
Wachsman M; Aurelian L; Smith CC; Lipinskas BR; Perkus ME; Paoletti E
J Infect Dis; 1987 Jun; 155(6):1188-97. PubMed ID: 3033094
[TBL] [Abstract][Full Text] [Related]
4. Expression of herpes simplex virus glycoprotein D on antigen presenting cells infected with vaccinia recombinants and protective immunity.
Wachsman M; Aurelian L; Hunter JC; Perkus ME; Paoletti E
Biosci Rep; 1988 Aug; 8(4):323-34. PubMed ID: 3263886
[TBL] [Abstract][Full Text] [Related]
5. Antigen-presenting capacity of epidermal cells infected with vaccinia virus recombinants containing the herpes simplex virus glycoprotein D, and protective immunity.
Wachsman M; Luo JH; Aurelian L; Perkus ME; Paoletti E
J Gen Virol; 1989 Sep; 70 ( Pt 9)():2513-20. PubMed ID: 2550579
[TBL] [Abstract][Full Text] [Related]
6. Protection from herpes simplex virus type 2 is associated with T cells involved in delayed type hypersensitivity that recognize glycosylation-related epitopes on glycoprotein D.
Wachsman M; Luo JH; Aurelian L; Paoletti E
Vaccine; 1992; 10(7):447-54. PubMed ID: 1376951
[TBL] [Abstract][Full Text] [Related]
7. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.
Rooney JF; Wohlenberg C; Cremer KJ; Moss B; Notkins AL
J Virol; 1988 May; 62(5):1530-4. PubMed ID: 2833606
[TBL] [Abstract][Full Text] [Related]
8. Live vaccinia virus recombinants expressing herpes simplex virus genes.
Rooney JF; Wohlenberg CR; Moss B; Notkins AL
Rev Infect Dis; 1991; 13 Suppl 11():S898-903. PubMed ID: 1664124
[TBL] [Abstract][Full Text] [Related]
9. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.
Peng T; Ponce-de-Leon M; Jiang H; Dubin G; Lubinski JM; Eisenberg RJ; Cohen GH
J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201
[TBL] [Abstract][Full Text] [Related]
10. The mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: clearance of local infection.
Martin S; Rouse BT
J Immunol; 1987 May; 138(10):3431-7. PubMed ID: 3033075
[TBL] [Abstract][Full Text] [Related]
11. Induction of protective immunity with antibody to herpes simplex virus type 1 glycoprotein H (gH) and analysis of the immune response to gH expressed in recombinant vaccinia virus.
Forrester AJ; Sullivan V; Simmons A; Blacklaws BA; Smith GL; Nash AA; Minson AC
J Gen Virol; 1991 Feb; 72 ( Pt 2)():369-75. PubMed ID: 1704412
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes.
Stanberry LR; Bernstein DI; Burke RL; Pachl C; Myers MG
J Infect Dis; 1987 May; 155(5):914-20. PubMed ID: 3031173
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of antiviral immunity using vaccinia virus recombinants expressing cloned genes for herpes simplex virus type 1 glycoproteins.
Martin S; Cantin E; Rouse BT
J Gen Virol; 1989 Jun; 70 ( Pt 6)():1359-70. PubMed ID: 2543783
[TBL] [Abstract][Full Text] [Related]
15. Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.
Hook LM; Cairns TM; Awasthi S; Brooks BD; Ditto NT; Eisenberg RJ; Cohen GH; Friedman HM
PLoS Pathog; 2018 May; 14(5):e1007095. PubMed ID: 29791513
[TBL] [Abstract][Full Text] [Related]
16. Intramuscular Immunization of Mice with the Live-Attenuated Herpes Simplex Virus 1 Vaccine Strain VC2 Expressing Equine Herpesvirus 1 (EHV-1) Glycoprotein D Generates Anti-EHV-1 Immune Responses in Mice.
Liu SA; Stanfield BA; Chouljenko VN; Naidu S; Langohr I; Del Piero F; Ferracone J; Roy AA; Kousoulas KG
J Virol; 2017 Jun; 91(12):. PubMed ID: 28404844
[TBL] [Abstract][Full Text] [Related]
17. Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity.
Allen EM; Weir JP; Martin S; Mercadal C; Rouse BT
Viral Immunol; 1990; 3(3):207-15. PubMed ID: 2175194
[TBL] [Abstract][Full Text] [Related]
18. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2.
Quenelle DC; Collins DJ; Marciani DJ; Kern ER
Vaccine; 2006 Mar; 24(10):1515-22. PubMed ID: 16288820
[TBL] [Abstract][Full Text] [Related]
19. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
